KalVista’s oral HAE drug is approved. Now five studies are testing what treatment changes in real life
KalVista and Chiesi are expanding sebetralstat research into patient satisfaction and quality of life. See what five ACAAI studies could reveal.
Pharma & Biotech
Pharma & Biotech
How Chiesi Global Rare Diseases is positioning lomitapide for earlier lifecycle management in HoFH
CHMP backs paediatric lomitapide for HoFH. Read what this means for clinicians, regulators, and rare disease access across Europe.
Pharma & Biotech
What the EU’s Elfabrio dosing update means for Fabry disease treatment burden
EU approves monthly Elfabrio dosing for Fabry disease. Discover how reduced infusion frequency could reshape enzyme therapy and treatment burden.